Market Outlook
The global Duchenne Muscular Dystrophy market size was valued at USD 1237.8 million in 2022 and is forecast to a readjusted size of USD 13240 million by 2029 with a CAGR of 40.3% during review period.
Duchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc. North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent. In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.
This report is a detailed and comprehensive analysis for global Duchenne Muscular Dystrophy market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Duchenne Muscular Dystrophy market size and forecasts, in consumption value ($ Million), sales quantity (K Doses), and average selling prices (USD/Dose), 2018-2029
Global Duchenne Muscular Dystrophy market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Doses), and average selling prices (USD/Dose), 2018-2029
Global Duchenne Muscular Dystrophy market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Doses), and average selling prices (USD/Dose), 2018-2029
Global Duchenne Muscular Dystrophy market shares of main players, shipments in revenue ($ Million), sales quantity (K Doses), and ASP (USD/Dose), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Duchenne Muscular Dystrophy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Duchenne Muscular Dystrophy market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Key Market Players
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Segmentation By Type
Exondys 51
Emflaza
Translarna
Segmentation By Application
Hospitals
Clinics
Home Care
Segmentation By Region
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Market SWOT Analysis
What are the strengths of the Duchenne Muscular Dystrophy (DMD) market in 2025?
The DMD market is supported by the increasing number of treatment options being developed, including gene therapies and exon-skipping drugs. The high unmet medical need drives strong investment and research focus, fostering innovation.
What are the weaknesses of the DMD market in 2025?
Despite advancements, DMD treatments remain expensive and have limited availability. Regulatory challenges, long development timelines, and high costs of clinical trials are significant barriers. Moreover, the complexity of gene therapies may limit their widespread adoption.
What are the opportunities for the DMD market in 2025?
The market offers considerable potential for new therapies, especially gene editing and innovative biologics, which could improve patient outcomes. Expanding awareness and diagnostic advancements also present opportunities to accelerate early treatment initiation, improving long-term patient care.
What are the threats to the DMD market in 2025?
The primary threats include the high cost of therapies, which could limit access, especially in emerging markets. There is also the challenge of managing side effects in new treatments and competition among various biopharmaceutical companies developing similar therapies.
Market PESTEL Analysis
What are the political factors affecting the Duchenne Muscular Dystrophy (DMD) market in 2025?
Political stability and healthcare policies in different regions play a crucial role in determining the accessibility and pricing of DMD treatments. Governments' commitment to funding rare disease research and patient access to expensive therapies impacts market growth.
What are the economic factors affecting the DMD market in 2025?
Economic challenges, such as the affordability of advanced treatments, can limit patient access in lower-income countries. High treatment costs and the economic burden of long-term care for DMD patients are critical factors influencing market dynamics.
What are the social factors affecting the DMD market in 2025?
Growing awareness about rare diseases and the importance of early diagnosis can improve patient outcomes and treatment adoption. The increasing prevalence of DMD diagnoses and social acceptance of new therapies also shape market trends.
What are the technological factors affecting the DMD market in 2025?
Advancements in gene therapy, CRISPR technology, and personalized medicine offer groundbreaking treatment possibilities for DMD. The development of more effective and less invasive therapies is expected to significantly impact market growth.
What are the environmental factors affecting the DMD market in 2025?
Sustainability concerns around the production and disposal of biologic therapies, including genetic modifications, could impact production costs. However, the environmental impact of manufacturing and distributing treatments is less prominent in the DMD market.
What are the legal factors affecting the DMD market in 2025?
Intellectual property laws and regulatory approval processes for gene therapies and new treatments are significant factors. The legal landscape surrounding patient rights, drug pricing, and reimbursement policies will influence market expansion and access to therapies.
Market SIPOC Analysis
Who are the suppliers in the Duchenne Muscular Dystrophy (DMD) market in 2025?
Suppliers include pharmaceutical companies, biotech firms, and research institutions that provide raw materials, drugs, and technologies for the development of DMD therapies. These suppliers also include genetic engineering firms that create specialized treatments like gene therapies.
What are the inputs for the DMD market in 2025?
Inputs comprise research data, clinical trials, raw materials for drug production, patient data, and regulatory approvals. Additionally, investment in gene therapy technologies, biomarkers for diagnostics, and innovations in drug delivery systems are key inputs.
Who are the process stakeholders in the DMD market in 2025?
Process stakeholders include pharmaceutical companies, clinical researchers, healthcare providers, genetic counselors, and regulatory bodies. Their collaboration in clinical trials, drug development, and patient care ensures the proper functioning of the DMD treatment landscape.
What are the outputs of the DMD market in 2025?
The outputs are innovative therapies like gene treatments, exon-skipping drugs, and biologics, which are intended to improve the quality of life for DMD patients. Also, improved diagnostic tools and better patient management practices are important outputs.
Who are the customers of the DMD market in 2025?
The customers are primarily DMD patients, caregivers, healthcare providers, and hospitals. Insurance companies and government health programs also play a role in the demand for DMD treatments, while researchers and academic institutions contribute to advancements.
Market Porter's Five Forces
What is the threat of new entrants in the Duchenne Muscular Dystrophy (DMD) market in 2025?
The threat of new entrants is moderate due to the high research and development costs associated with DMD treatments. The complexity of developing effective therapies, combined with stringent regulatory requirements, creates significant barriers to entry for new players.
What is the bargaining power of suppliers in the DMD market in 2025?
The bargaining power of suppliers is moderate. While there are a few key suppliers of raw materials and specialized technologies, the growing demand for gene therapies and biologics for DMD treatments has led to an increase in competition among suppliers, balancing their power.
What is the bargaining power of buyers in the DMD market in 2025?
The bargaining power of buyers, particularly patients and healthcare providers, is low to moderate. Given the niche nature of DMD treatments and the high cost of therapies, patients often have limited choices, reducing their negotiating power. However, insurers may have more influence in certain markets.
What is the threat of substitute products in the DMD market in 2025?
The threat of substitutes is low. While there are other treatments available for managing symptoms, such as corticosteroids, there are currently no direct substitutes that offer the same potential for long-term disease modification as the emerging gene therapies and exon-skipping drugs.
What is the intensity of competitive rivalry in the DMD market in 2025?
The intensity of competitive rivalry is high. Several established pharmaceutical and biotech companies are competing to develop the most effective and affordable DMD therapies. With a limited patient pool and high research costs, companies are striving to gain market share through differentiation and innovation.
Market Upstream Analysis
What are the key suppliers in the Duchenne Muscular Dystrophy (DMD) market in 2025?
Key suppliers include biotech firms, pharmaceutical companies, and research institutions specializing in genetic therapies, molecular diagnostics, and biologics. They provide the necessary research, technologies, and raw materials required for developing DMD treatments.
What are the main raw materials and technologies required for the DMD market in 2025?
The main raw materials and technologies include gene-editing tools like CRISPR, biologic compounds, and synthetic drugs. Technologies for gene delivery systems, clinical trial data management, and diagnostic tools such as biomarkers also play a crucial role in the upstream process.
What are the challenges faced by suppliers in the DMD market in 2025?
Suppliers face challenges such as high R&D costs, regulatory hurdles, and the complexity of producing specialized gene therapies. The need for extensive clinical trials, long approval timelines, and the limited patient population also impact supply chain dynamics and costs.
What are the key regulatory and environmental factors affecting the upstream in the DMD market in 2025?
Regulatory factors include the need for FDA and EMA approvals for novel therapies, as well as compliance with strict manufacturing guidelines for gene therapies. Environmental considerations involve sustainable production practices and the safe disposal of genetically modified materials.
What role do partnerships and collaborations play in the upstream of the DMD market in 2025?
Partnerships and collaborations between pharmaceutical companies, academic institutions, and technology providers are vital in advancing DMD research and development. They help share resources, mitigate risks, and accelerate the development of innovative therapies, particularly in gene editing and biologics.
Market Midstream Analysis
What are the key processes involved in the Duchenne Muscular Dystrophy (DMD) market in 2025?
The key processes include the clinical development of new therapies, such as gene therapies and exon-skipping drugs, clinical trials, regulatory approvals, and patient recruitment. Additionally, distribution channels for DMD treatments and ongoing patient monitoring and care are essential processes.
What are the major challenges faced in the midstream of the DMD market in 2025?
Challenges include the complexity and cost of clinical trials, which can delay time-to-market for new therapies. Limited patient populations for trials, high production costs for advanced biologics, and regulatory hurdles for gene-based treatments add further pressure on the midstream processes.
What role do healthcare providers play in the DMD market in 2025?
Healthcare providers are crucial in diagnosing DMD early, managing ongoing patient care, and facilitating access to new treatments. They also play a key role in educating patients and caregivers about available therapies and ensuring proper use of newly approved treatments.
What are the key distribution channels for DMD treatments in 2025?
Distribution channels primarily involve specialized pharmaceutical wholesalers, hospitals, and pharmacies. Increasingly, direct-to-patient services are being utilized, especially for biologic treatments and gene therapies that require careful management and distribution.
How do regulatory bodies impact the midstream of the DMD market in 2025?
Regulatory bodies like the FDA and EMA impact the midstream by setting standards for drug approval, clinical trial design, and patient safety. Delays or changes in regulatory requirements can significantly influence the speed at which therapies become available to patients.
Market Downstream Analysis
What are the key customer segments in the Duchenne Muscular Dystrophy (DMD) market in 2025?
Key customer segments include DMD patients and their families, healthcare providers, hospitals, and specialty clinics. Insurance companies also play a vital role in determining patient access to therapies, while research organizations are customers for clinical data and treatment innovations.
What are the main factors influencing customer demand for DMD treatments in 2025?
Customer demand is primarily influenced by the efficacy, safety, and cost of available therapies. Additionally, awareness and early diagnosis, as well as the growing acceptance of gene therapies, are important factors that drive demand for more advanced and effective treatment options.
What are the challenges faced by customers in the DMD market in 2025?
Challenges for customers include the high cost of treatments, limited access to specialized care in certain regions, and the need for ongoing treatment and monitoring. There is also the challenge of navigating insurance coverage, which may limit access to newer therapies.
What role do healthcare providers play in the downstream of the DMD market in 2025?
Healthcare providers play a critical role in diagnosing DMD, recommending appropriate treatments, and managing long-term care. They are essential in educating patients about new therapies, monitoring treatment progress, and ensuring that patients adhere to complex treatment regimens.
How do distribution channels affect the downstream in the DMD market in 2025?
Distribution channels, including hospitals, specialized clinics, and pharmacies, ensure that therapies reach patients. Direct-to-patient services are becoming more prominent for gene therapies, where treatments require careful administration and follow-up, impacting how quickly and effectively treatments are delivered.
Chapter 1, to describe Duchenne Muscular Dystrophy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Duchenne Muscular Dystrophy, with price, sales, revenue and global market share of Duchenne Muscular Dystrophy from 2018 to 2023.
Chapter 3, the Duchenne Muscular Dystrophy competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Duchenne Muscular Dystrophy breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Duchenne Muscular Dystrophy market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Duchenne Muscular Dystrophy.
Chapter 14 and 15, to describe Duchenne Muscular Dystrophy sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Duchenne Muscular Dystrophy
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Duchenne Muscular Dystrophy Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Exondys 51
1.3.3 Emflaza
1.3.4 Translarna
1.4 Market Analysis by Application
1.4.1 Overview: Global Duchenne Muscular Dystrophy Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 Home Care
1.5 Global Duchenne Muscular Dystrophy Market Size & Forecast
1.5.1 Global Duchenne Muscular Dystrophy Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Duchenne Muscular Dystrophy Sales Quantity (2018-2029)
1.5.3 Global Duchenne Muscular Dystrophy Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Sarepta Therapeutics
2.1.1 Sarepta Therapeutics Details
2.1.2 Sarepta Therapeutics Major Business
2.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Product and Services
2.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sarepta Therapeutics Recent Developments/Updates
2.2 PTC Therapeutics
2.2.1 PTC Therapeutics Details
2.2.2 PTC Therapeutics Major Business
2.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Product and Services
2.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 PTC Therapeutics Recent Developments/Updates
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Duchenne Muscular Dystrophy Product and Services
2.3.4 Pfizer Duchenne Muscular Dystrophy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer Recent Developments/Updates
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product and Services
2.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Bristol-Myers Squibb Recent Developments/Updates
2.5 Italfarmaco
2.5.1 Italfarmaco Details
2.5.2 Italfarmaco Major Business
2.5.3 Italfarmaco Duchenne Muscular Dystrophy Product and Services
2.5.4 Italfarmaco Duchenne Muscular Dystrophy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Italfarmaco Recent Developments/Updates
2.6 Santhera Pharmaceuticals
2.6.1 Santhera Pharmaceuticals Details
2.6.2 Santhera Pharmaceuticals Major Business
2.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product and Services
2.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Santhera Pharmaceuticals Recent Developments/Updates
3 Competitive Environment: Duchenne Muscular Dystrophy by Manufacturer
3.1 Global Duchenne Muscular Dystrophy Sales Quantity by Manufacturer (2018-2023)
3.2 Global Duchenne Muscular Dystrophy Revenue by Manufacturer (2018-2023)
3.3 Global Duchenne Muscular Dystrophy Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Duchenne Muscular Dystrophy by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Duchenne Muscular Dystrophy Manufacturer Market Share in 2022
3.4.2 Top 6 Duchenne Muscular Dystrophy Manufacturer Market Share in 2022
3.5 Duchenne Muscular Dystrophy Market: Overall Company Footprint Analysis
3.5.1 Duchenne Muscular Dystrophy Market: Region Footprint
3.5.2 Duchenne Muscular Dystrophy Market: Company Product Type Footprint
3.5.3 Duchenne Muscular Dystrophy Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Duchenne Muscular Dystrophy Market Size by Region
4.1.1 Global Duchenne Muscular Dystrophy Sales Quantity by Region (2018-2029)
4.1.2 Global Duchenne Muscular Dystrophy Consumption Value by Region (2018-2029)
4.1.3 Global Duchenne Muscular Dystrophy Average Price by Region (2018-2029)
4.2 North America Duchenne Muscular Dystrophy Consumption Value (2018-2029)
4.3 Europe Duchenne Muscular Dystrophy Consumption Value (2018-2029)
4.4 Asia-Pacific Duchenne Muscular Dystrophy Consumption Value (2018-2029)
4.5 South America Duchenne Muscular Dystrophy Consumption Value (2018-2029)
4.6 Middle East and Africa Duchenne Muscular Dystrophy Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Duchenne Muscular Dystrophy Sales Quantity by Type (2018-2029)
5.2 Global Duchenne Muscular Dystrophy Consumption Value by Type (2018-2029)
5.3 Global Duchenne Muscular Dystrophy Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Duchenne Muscular Dystrophy Sales Quantity by Application (2018-2029)
6.2 Global Duchenne Muscular Dystrophy Consumption Value by Application (2018-2029)
6.3 Global Duchenne Muscular Dystrophy Average Price by Application (2018-2029)
7 North America
7.1 North America Duchenne Muscular Dystrophy Sales Quantity by Type (2018-2029)
7.2 North America Duchenne Muscular Dystrophy Sales Quantity by Application (2018-2029)
7.3 North America Duchenne Muscular Dystrophy Market Size by Country
7.3.1 North America Duchenne Muscular Dystrophy Sales Quantity by Country (2018-2029)
7.3.2 North America Duchenne Muscular Dystrophy Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Duchenne Muscular Dystrophy Sales Quantity by Type (2018-2029)
8.2 Europe Duchenne Muscular Dystrophy Sales Quantity by Application (2018-2029)
8.3 Europe Duchenne Muscular Dystrophy Market Size by Country
8.3.1 Europe Duchenne Muscular Dystrophy Sales Quantity by Country (2018-2029)
8.3.2 Europe Duchenne Muscular Dystrophy Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Duchenne Muscular Dystrophy Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Duchenne Muscular Dystrophy Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Duchenne Muscular Dystrophy Market Size by Region
9.3.1 Asia-Pacific Duchenne Muscular Dystrophy Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Duchenne Muscular Dystrophy Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Duchenne Muscular Dystrophy Sales Quantity by Type (2018-2029)
10.2 South America Duchenne Muscular Dystrophy Sales Quantity by Application (2018-2029)
10.3 South America Duchenne Muscular Dystrophy Market Size by Country
10.3.1 South America Duchenne Muscular Dystrophy Sales Quantity by Country (2018-2029)
10.3.2 South America Duchenne Muscular Dystrophy Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Duchenne Muscular Dystrophy Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Duchenne Muscular Dystrophy Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Duchenne Muscular Dystrophy Market Size by Country
11.3.1 Middle East & Africa Duchenne Muscular Dystrophy Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Duchenne Muscular Dystrophy Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Duchenne Muscular Dystrophy Market Drivers
12.2 Duchenne Muscular Dystrophy Market Restraints
12.3 Duchenne Muscular Dystrophy Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Duchenne Muscular Dystrophy and Key Manufacturers
13.2 Manufacturing Costs Percentage of Duchenne Muscular Dystrophy
13.3 Duchenne Muscular Dystrophy Production Process
13.4 Duchenne Muscular Dystrophy Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Duchenne Muscular Dystrophy Typical Distributors
14.3 Duchenne Muscular Dystrophy Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Duchenne Muscular Dystrophy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Duchenne Muscular Dystrophy Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Sarepta Therapeutics Basic Information, Manufacturing Base and Competitors
Table 4. Sarepta Therapeutics Major Business
Table 5. Sarepta Therapeutics Duchenne Muscular Dystrophy Product and Services
Table 6. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Sarepta Therapeutics Recent Developments/Updates
Table 8. PTC Therapeutics Basic Information, Manufacturing Base and Competitors
Table 9. PTC Therapeutics Major Business
Table 10. PTC Therapeutics Duchenne Muscular Dystrophy Product and Services
Table 11. PTC Therapeutics Duchenne Muscular Dystrophy Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. PTC Therapeutics Recent Developments/Updates
Table 13. Pfizer Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer Major Business
Table 15. Pfizer Duchenne Muscular Dystrophy Product and Services
Table 16. Pfizer Duchenne Muscular Dystrophy Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Pfizer Recent Developments/Updates
Table 18. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 19. Bristol-Myers Squibb Major Business
Table 20. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product and Services
Table 21. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Bristol-Myers Squibb Recent Developments/Updates
Table 23. Italfarmaco Basic Information, Manufacturing Base and Competitors
Table 24. Italfarmaco Major Business
Table 25. Italfarmaco Duchenne Muscular Dystrophy Product and Services
Table 26. Italfarmaco Duchenne Muscular Dystrophy Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Italfarmaco Recent Developments/Updates
Table 28. Santhera Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 29. Santhera Pharmaceuticals Major Business
Table 30. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product and Services
Table 31. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Santhera Pharmaceuticals Recent Developments/Updates
Table 33. Global Duchenne Muscular Dystrophy Sales Quantity by Manufacturer (2018-2023) & (K Doses)
Table 34. Global Duchenne Muscular Dystrophy Revenue by Manufacturer (2018-2023) & (USD Million)
Table 35. Global Duchenne Muscular Dystrophy Average Price by Manufacturer (2018-2023) & (USD/Dose)
Table 36. Market Position of Manufacturers in Duchenne Muscular Dystrophy, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 37. Head Office and Duchenne Muscular Dystrophy Production Site of Key Manufacturer
Table 38. Duchenne Muscular Dystrophy Market: Company Product Type Footprint
Table 39. Duchenne Muscular Dystrophy Market: Company Product Application Footprint
Table 40. Duchenne Muscular Dystrophy New Market Entrants and Barriers to Market Entry
Table 41. Duchenne Muscular Dystrophy Mergers, Acquisition, Agreements, and Collaborations
Table 42. Global Duchenne Muscular Dystrophy Sales Quantity by Region (2018-2023) & (K Doses)
Table 43. Global Duchenne Muscular Dystrophy Sales Quantity by Region (2024-2029) & (K Doses)
Table 44. Global Duchenne Muscular Dystrophy Consumption Value by Region (2018-2023) & (USD Million)
Table 45. Global Duchenne Muscular Dystrophy Consumption Value by Region (2024-2029) & (USD Million)
Table 46. Global Duchenne Muscular Dystrophy Average Price by Region (2018-2023) & (USD/Dose)
Table 47. Global Duchenne Muscular Dystrophy Average Price by Region (2024-2029) & (USD/Dose)
Table 48. Global Duchenne Muscular Dystrophy Sales Quantity by Type (2018-2023) & (K Doses)
Table 49. Global Duchenne Muscular Dystrophy Sales Quantity by Type (2024-2029) & (K Doses)
Table 50. Global Duchenne Muscular Dystrophy Consumption Value by Type (2018-2023) & (USD Million)
Table 51. Global Duchenne Muscular Dystrophy Consumption Value by Type (2024-2029) & (USD Million)
Table 52. Global Duchenne Muscular Dystrophy Average Price by Type (2018-2023) & (USD/Dose)
Table 53. Global Duchenne Muscular Dystrophy Average Price by Type (2024-2029) & (USD/Dose)
Table 54. Global Duchenne Muscular Dystrophy Sales Quantity by Application (2018-2023) & (K Doses)
Table 55. Global Duchenne Muscular Dystrophy Sales Quantity by Application (2024-2029) & (K Doses)
Table 56. Global Duchenne Muscular Dystrophy Consumption Value by Application (2018-2023) & (USD Million)
Table 57. Global Duchenne Muscular Dystrophy Consumption Value by Application (2024-2029) & (USD Million)
Table 58. Global Duchenne Muscular Dystrophy Average Price by Application (2018-2023) & (USD/Dose)
Table 59. Global Duchenne Muscular Dystrophy Average Price by Application (2024-2029) & (USD/Dose)
Table 60. North America Duchenne Muscular Dystrophy Sales Quantity by Type (2018-2023) & (K Doses)
Table 61. North America Duchenne Muscular Dystrophy Sales Quantity by Type (2024-2029) & (K Doses)
Table 62. North America Duchenne Muscular Dystrophy Sales Quantity by Application (2018-2023) & (K Doses)
Table 63. North America Duchenne Muscular Dystrophy Sales Quantity by Application (2024-2029) & (K Doses)
Table 64. North America Duchenne Muscular Dystrophy Sales Quantity by Country (2018-2023) & (K Doses)
Table 65. North America Duchenne Muscular Dystrophy Sales Quantity by Country (2024-2029) & (K Doses)
Table 66. North America Duchenne Muscular Dystrophy Consumption Value by Country (2018-2023) & (USD Million)
Table 67. North America Duchenne Muscular Dystrophy Consumption Value by Country (2024-2029) & (USD Million)
Table 68. Europe Duchenne Muscular Dystrophy Sales Quantity by Type (2018-2023) & (K Doses)
Table 69. Europe Duchenne Muscular Dystrophy Sales Quantity by Type (2024-2029) & (K Doses)
Table 70. Europe Duchenne Muscular Dystrophy Sales Quantity by Application (2018-2023) & (K Doses)
Table 71. Europe Duchenne Muscular Dystrophy Sales Quantity by Application (2024-2029) & (K Doses)
Table 72. Europe Duchenne Muscular Dystrophy Sales Quantity by Country (2018-2023) & (K Doses)
Table 73. Europe Duchenne Muscular Dystrophy Sales Quantity by Country (2024-2029) & (K Doses)
Table 74. Europe Duchenne Muscular Dystrophy Consumption Value by Country (2018-2023) & (USD Million)
Table 75. Europe Duchenne Muscular Dystrophy Consumption Value by Country (2024-2029) & (USD Million)
Table 76. Asia-Pacific Duchenne Muscular Dystrophy Sales Quantity by Type (2018-2023) & (K Doses)
Table 77. Asia-Pacific Duchenne Muscular Dystrophy Sales Quantity by Type (2024-2029) & (K Doses)
Table 78. Asia-Pacific Duchenne Muscular Dystrophy Sales Quantity by Application (2018-2023) & (K Doses)
Table 79. Asia-Pacific Duchenne Muscular Dystrophy Sales Quantity by Application (2024-2029) & (K Doses)
Table 80. Asia-Pacific Duchenne Muscular Dystrophy Sales Quantity by Region (2018-2023) & (K Doses)
Table 81. Asia-Pacific Duchenne Muscular Dystrophy Sales Quantity by Region (2024-2029) & (K Doses)
Table 82. Asia-Pacific Duchenne Muscular Dystrophy Consumption Value by Region (2018-2023) & (USD Million)
Table 83. Asia-Pacific Duchenne Muscular Dystrophy Consumption Value by Region (2024-2029) & (USD Million)
Table 84. South America Duchenne Muscular Dystrophy Sales Quantity by Type (2018-2023) & (K Doses)
Table 85. South America Duchenne Muscular Dystrophy Sales Quantity by Type (2024-2029) & (K Doses)
Table 86. South America Duchenne Muscular Dystrophy Sales Quantity by Application (2018-2023) & (K Doses)
Table 87. South America Duchenne Muscular Dystrophy Sales Quantity by Application (2024-2029) & (K Doses)
Table 88. South America Duchenne Muscular Dystrophy Sales Quantity by Country (2018-2023) & (K Doses)
Table 89. South America Duchenne Muscular Dystrophy Sales Quantity by Country (2024-2029) & (K Doses)
Table 90. South America Duchenne Muscular Dystrophy Consumption Value by Country (2018-2023) & (USD Million)
Table 91. South America Duchenne Muscular Dystrophy Consumption Value by Country (2024-2029) & (USD Million)
Table 92. Middle East & Africa Duchenne Muscular Dystrophy Sales Quantity by Type (2018-2023) & (K Doses)
Table 93. Middle East & Africa Duchenne Muscular Dystrophy Sales Quantity by Type (2024-2029) & (K Doses)
Table 94. Middle East & Africa Duchenne Muscular Dystrophy Sales Quantity by Application (2018-2023) & (K Doses)
Table 95. Middle East & Africa Duchenne Muscular Dystrophy Sales Quantity by Application (2024-2029) & (K Doses)
Table 96. Middle East & Africa Duchenne Muscular Dystrophy Sales Quantity by Region (2018-2023) & (K Doses)
Table 97. Middle East & Africa Duchenne Muscular Dystrophy Sales Quantity by Region (2024-2029) & (K Doses)
Table 98. Middle East & Africa Duchenne Muscular Dystrophy Consumption Value by Region (2018-2023) & (USD Million)
Table 99. Middle East & Africa Duchenne Muscular Dystrophy Consumption Value by Region (2024-2029) & (USD Million)
Table 100. Duchenne Muscular Dystrophy Raw Material
Table 101. Key Manufacturers of Duchenne Muscular Dystrophy Raw Materials
Table 102. Duchenne Muscular Dystrophy Typical Distributors
Table 103. Duchenne Muscular Dystrophy Typical Customers
List of Figures
Figure 1. Duchenne Muscular Dystrophy Picture
Figure 2. Global Duchenne Muscular Dystrophy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Duchenne Muscular Dystrophy Consumption Value Market Share by Type in 2022
Figure 4. Exondys 51 Examples
Figure 5. Emflaza Examples
Figure 6. Translarna Examples
Figure 7. Global Duchenne Muscular Dystrophy Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Duchenne Muscular Dystrophy Consumption Value Market Share by Application in 2022
Figure 9. Hospitals Examples
Figure 10. Clinics Examples
Figure 11. Home Care Examples
Figure 12. Global Duchenne Muscular Dystrophy Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Duchenne Muscular Dystrophy Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Duchenne Muscular Dystrophy Sales Quantity (2018-2029) & (K Doses)
Figure 15. Global Duchenne Muscular Dystrophy Average Price (2018-2029) & (USD/Dose)
Figure 16. Global Duchenne Muscular Dystrophy Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Duchenne Muscular Dystrophy Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Duchenne Muscular Dystrophy by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Duchenne Muscular Dystrophy Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Duchenne Muscular Dystrophy Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Duchenne Muscular Dystrophy Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Duchenne Muscular Dystrophy Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Duchenne Muscular Dystrophy Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Duchenne Muscular Dystrophy Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Duchenne Muscular Dystrophy Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Duchenne Muscular Dystrophy Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Duchenne Muscular Dystrophy Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Duchenne Muscular Dystrophy Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Duchenne Muscular Dystrophy Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Duchenne Muscular Dystrophy Average Price by Type (2018-2029) & (USD/Dose)
Figure 31. Global Duchenne Muscular Dystrophy Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Duchenne Muscular Dystrophy Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Duchenne Muscular Dystrophy Average Price by Application (2018-2029) & (USD/Dose)
Figure 34. North America Duchenne Muscular Dystrophy Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Duchenne Muscular Dystrophy Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Duchenne Muscular Dystrophy Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Duchenne Muscular Dystrophy Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Duchenne Muscular Dystrophy Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Duchenne Muscular Dystrophy Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Duchenne Muscular Dystrophy Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Duchenne Muscular Dystrophy Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Duchenne Muscular Dystrophy Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Duchenne Muscular Dystrophy Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Duchenne Muscular Dystrophy Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Duchenne Muscular Dystrophy Consumption Value Market Share by Region (2018-2029)
Figure 54. China Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Duchenne Muscular Dystrophy Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Duchenne Muscular Dystrophy Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Duchenne Muscular Dystrophy Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Duchenne Muscular Dystrophy Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Duchenne Muscular Dystrophy Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Duchenne Muscular Dystrophy Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Duchenne Muscular Dystrophy Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Duchenne Muscular Dystrophy Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Duchenne Muscular Dystrophy Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Duchenne Muscular Dystrophy Market Drivers
Figure 75. Duchenne Muscular Dystrophy Market Restraints
Figure 76. Duchenne Muscular Dystrophy Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy in 2022
Figure 79. Manufacturing Process Analysis of Duchenne Muscular Dystrophy
Figure 80. Duchenne Muscular Dystrophy Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
